About ImmuONE
ImmuONE is a Healthcare company based in Hatfield (United Kingdom) founded in 2019 by Abigail Martin. Innovative inhalation safety solutions are developed by ImmuONE. ImmuONE has raised $3.2 million across 2 funding rounds from investors including Mercia, Midlands Engine Investment Fund and Pioneer Group. Its chief executive, as recorded, is Abigail Martin. ImmuONE offers products and services including ImmuPHAGEâ„¢, ImmuLUNGâ„¢, LipidONEâ„¢, and Assay Development. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and In Vitro Assays. Its legal entity is IMMUONE LTD. Its competitors include Metrion Biosciences, Antibody Analytics and Clyde Biosciences; 2 of its 3 listed competitors have raised funding.
Company details
ImmuONE was established in 2019 in Hatfield, United Kingdom, as a biotech contract research organization. Focus is placed on solutions for inhalation safety, including the ImmuLUNG cell model used to predict interactions between lung epithelial and immune cells. Operations involve advanced scientific research by experienced professionals in the respiratory health sector. Services support drug development and toxicity assessments for inhaled substances.
- Headquarters Hatfield, United Kingdom
- Founders Abigail Martin
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website immuone.com
- Social LinkedIn X YouTube
- Legal Name Immuone Ltd
- Date of Incorporation 01 Apr, 2019
- Jurisdiction MILTON KEYNES, ENGLAND
- Total Equity Funding$3.2M (USD)
in 2 rounds
- Latest Funding Round$776.77K (USD), Seed
Mar 2025
- InvestorsMercia
& 2 more
Products & Services of ImmuONE
ImmuONE offers a comprehensive portfolio of products and services, including ImmuPHAGE™, ImmuLUNG™, LipidONE™, and Assay Development.
Analyzes macrophage responses to inhaled substances in lungs.
Models immune responses in alveolar tissue for safety assessments.
Supports biochemical analysis in inhalation toxicology studies.
Develops tests for inflammation and immune response evaluations.
Apps and channels of ImmuONE
its YouTube channel ImmuONE has 8 subscribers and 4 videos.
Videos from ImmuONE
The most watched videos on ImmuONE's YouTube channel, ImmuONE (8 subscribers). Click a video to play it here.
More on ImmuONE.
Funding Insights of ImmuONE
ImmuONE has successfully raised a total of $3.2M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $776.77 thousand completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.2M
- Total Rounds 2
- Last Round Seed — $776,772
- First Round $2.43M
(Oct 2023)
- Investors Count 3
All 2 funding rounds of ImmuONE with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2025 | $776,772 | Seed | – | – | |
| Oct 2023 | $2.43M | Seed | – | Mercia |
3 investors in total: 3 institutional.
Investors in ImmuONE
ImmuONE has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, Midlands Engine Investment Fund and Pioneer Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment funding is provided to support Midlands SMEs growth. | meif.co.uk | Sheffield, United Kingdom | ||
| thepioneergroup.com | ||||
Investment management services are provided by Mercia to various clients. | 1982 | mercia.co.uk |
Investor details for ImmuONE
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ImmuONE
7 people are tracked at ImmuONE (2 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Abigail Martin | Co-Founder & CEO | Leadership |
Victoria Hutter | CSO & Co-Founder | Leadership |
Nilab Haydare | Junior Scientist | Team |
Ewelina Hoffman | Principal Lead Scientist | Team |
Amjad Saeed | Junior Scientist | Team |
Toba Shahbaz | Summer Research Student | Team |
Rhamiya Mahendran | Commercial Toxicology Lead | Team |
Complete people profiles for ImmuONE
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ImmuONE
3 dated milestones of ImmuONE across 6 years, from founding to its latest funding, stage changes and deals.
- Founded ImmuONE is founded.
- Funding First funding round of $2.4M.
- Funding Latest funding round, Seed, of $777K.
Competitors of ImmuONE
ImmuONE has 3 listed competitors in our database, 2 of them funded. They include Metrion Biosciences, Antibody Analytics and Clyde Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| metrionbiosciences.com | 2015 | Cambridge, United Kingdom | $8.44M | Ion channel screening and cardiac safety profiling services are provided. | ||
| antibodyanalytics.com | 2015 | Lanark, United Kingdom | 60 | Antibody analytics and characterization services are provided. | ||
| clydebio.com | 2012 | Holytown, United Kingdom | $3.5M | 6 | Cardiac safety testing is conducted using iPS-derived heart cells. |
Detailed competitors of ImmuONE
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immuone
Complete news archive for ImmuONE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImmuONE
ImmuONE was founded in 2019 and raised its 1st funding round 4 years after it was founded.
ImmuONE is headquartered in Hatfield, United Kingdom.
Abigail Martin is the CEO of ImmuONE, as recorded in our data. They have also founded this company.
ImmuONE is a funded company, having raised a total of $3.2M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.43M, raised on Oct 2023.
ImmuONE was established in 2019 in Hatfield, United Kingdom, as a biotech contract research organization. Focus is placed on solutions for inhalation safety, including the ImmuLUNG cell model used to predict interactions between lung epithelial and immune cells. Operations involve advanced scientific research by experienced professionals in the respiratory health sector. Services support drug development and toxicity assessments for inhaled substances.
ImmuONE's top competitors include Metrion Biosciences, Clyde Biosciences and Antibody Analytics.
ImmuONE offers ImmuPHAGEâ„¢, ImmuLUNGâ„¢, LipidONEâ„¢, and Assay Development.
ImmuONE has 3 investors. Key investors include Mercia, Midlands Engine Investment Fund, and Pioneer Group.
ImmuONE operates through Immuone Ltd.